Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 6, 2026Blood

ELN-DAVID Recommendations for NGS-based FLT3-ITD MRD Testing in Patients with Acute Myeloid Leukemia

View Full Paper
Ask AI
Bookmark
Share

Authors

CHChristopher S. HouriganLBLisanne BeugelinkJOJad Othman

Discussion

Loading...

Member takes

Overview

Technical note provides recommendations for MRD testing in AML patients in remission, indicating clinical standards.

Key Points

  • This paper outlines updated recommendations for FLT3-ITD MRD testing in patients with acute myeloid leukemia.
  • Updated clinical standard of care guidelines for MRD testing.
  • Laboratory recommendations for FLT3-ITD testing.
  • Clinical recommendations for monitoring patients in remission.
  • Guidelines emphasize the importance of accurate MRD testing for detecting residual disease in AML patients.
  • Standardized protocols for NGS-based testing are proposed to improve diagnostic accuracy.
  • Recommendations aim to enhance patient management and treatment outcomes in AML.

Cite This Study

Hourigan et al. (2026) studied this question.

synapsesocial.com/papers/6a23bb4471a5da9775e76df1https://doi.org/10.1182/blood.2026033569
View Full Paper
Ask AI
Bookmark
Share